MKK900 60 µg
Phase 1Biologic
MKK900 60 µg is one of 7 biologic programs targeting Respiratory Syncytial Virus (RSV). It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
6
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
7 competitors in Respiratory Syncytial Virus (RSV)
#DrugCompanyPhaseTrials
1BEYFORTUS
SanofiApproved
Rsvpref
PfizerPhase 3
Mrna-1345
ModernaPhase 3
Rsvpref Vaccine
PfizerPhase 3
Mrna-1365
ModernaPhase 1
MKK900 60 µg
MMAXVAX Biotechnology Limited Liability Company
Phase 1
Palivizumab /kg
AstraZenecaPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for MKK900 60 µg. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details